Open AccessParallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M‐induced resistance
Author(s) -
Xu Xiao
Publication year - 2015
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1186/s40880-015-0029-3
Subject(s) - t790m , clinical trial , lung cancer , epidermal growth factor receptor , medicine , cancer research , egfr inhibitors , oncology , pharmacology , cancer , gefitinib
Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clinical trial in both China and the United States, and the phase 1 trials were initiated in both countries in parallel. In the preclinical studies, avitinib showed three novel features including (1) irreversibly binding EGFR by forming a covalent bound with Cys 797 in the ATP‐binding pocket, (2) sparing wild‐type EGFR , and (3) overcoming T790M‐induced resistance. Avitinib is the first China‐developed novel EGFR inhibitor that has entered in global clinical trials, and will provide a precision targeted therapy for non‐small cell lung cancer patients.